Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
Status:
Completed
Trial end date:
2021-10-08
Target enrollment:
Participant gender:
Summary
This is a phase 2, single or multi-center, randomized, double-blind placebo-controlled study
to evaluate the safety and efficacy of Rayaldee (CTAP101 Capsules) to treat adult subjects
with mild to moderate COVID-19 who test positive for SARS-CoV-2 via nasopharynx swab and
subsequent reverse transcription polymerase chain reaction (RT-PCR).